Post-mortem ABCB1 genotyping reveals an elevated toxicity for female digoxin users

Area of Science:

• Pharmacogenomics
• Toxicology
• Molecular Biology

Background:

• P-glycoprotein, a key transporter molecule, influences drug metabolism in humans.
• Polymorphisms in the ABCB1 gene (MDR1) affect how individuals process medications.
• This study investigates the impact of ABCB1 single nucleotide polymorphisms (SNPs) on digoxin-related fatalities.

Purpose of the Study:

• To evaluate the association between ABCB1 gene polymorphisms and post-mortem digoxin concentrations.
• To determine if specific ABCB1 SNPs correlate with increased risk of digoxin toxicity.
• To explore potential gender differences in the impact of ABCB1 polymorphisms on digoxin levels.

Main Methods:

• Genotyping of three ABCB1 SNPs (3435C>T, 1236C>T, 2677G>T) using RT-PCR in 112 deceased Finnish subjects.
• Analysis of post-mortem blood samples from individuals with confirmed digoxin presence.
• Comparison of mutant allele and haplotype frequencies with a control group of 143 Finnish individuals.

Main Results:

• A positive correlation was observed between mutant ABCB1 genotype frequencies and post-mortem digoxin concentrations for all studied SNPs.
• Female subjects exhibited a more pronounced association, indicating a potentially higher risk of digoxin intoxication.
• Haplotype analysis further supported the link between specific ABCB1 variants and elevated digoxin levels.

Conclusions:

• ABCB1 polymorphisms are associated with increased mortality risk related to digoxin.
• Individualized genetic profiling for ABCB1 may be beneficial before initiating digoxin therapy.
• Gender-specific genotyping studies are valuable for establishing drug safety and determining cause of death in medico-legal cases.